Interferon alpha-2a biosimilar (Rhein Minapharm Biogenetics)

干扰素α-2a生物类似药 (Rhein Minapharm Biogenetics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon alpha-2a biosimilar (Rhein Minapharm Biogenetics)

Drug Alias Name干扰素α-2a生物仿制药 (Rhein Minapharm Biogenetics)Hansenula-derived interferon alpha-2aIFN-alpha-2a biosimilar (Rhein Minapharm Biogenetics)Interferon alfa-2a biosimilar (Rhein Minapharm Biogenetics)Reiferon

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists

TargetsInterferon alpha/beta receptor

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsHepatitis C

Approved Indications in ChinaN/A

Original Approved Country/TerritoryEgypt

Original Approved Date2005/01/01

Country/TerritoryEgypt

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesRhein Minapharm Biogenetics

China Registration ClassN/A

Develop Information

Active CompaniesRhein Minapharm Biogenetics

Inactive CompaniesN/A

Active IndicationsHepatitis C

Inactive IndicationsN/A

Other Information

ATC CodeL03AB04